AIM
KERX

Advantage Investment Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Advantage Investment Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-9,053
Closed -$34K – 1106
2018
Q2 		$34K Sell
9,053
-83,492
-90% -$407K 0.02% 440
2018
Q1 		$379K Buy
92,545
+13,369
+17% +$62.3K 0.14% 118
2017
Q4 		$368K Buy
79,176
+5,997
+8% +$33K 0.11% 126
2017
Q3 		$520K Buy
73,179
+2,542
+4% +$18.3K 0.17% 101
2017
Q2 		$511K Buy
70,637
+4,947
+8% +$30.9K 0.18% 99
2017
Q1 		$405K Buy
65,690
+10,934
+20% +$59.9K 0.16% 107
2016
Q4 		$321K Buy
54,756
+9,596
+21% +$52.4K 0.12% 113
2016
Q3 		$240K Buy
45,160
+2,598
+6% +$14K 0.09% 124
2016
Q2 		$282K Buy
42,562
+124
+0.3% +$693 0.13% 112
2016
Q1 		$198K Buy
42,438
+9,936
+31% +$39.7K 0.08% 129
2015
Q4 		$164K Sell
32,502
-565
-2% -$2.68K 0.09% 151
2015
Q3 		$116K Buy
33,067
+22,358
+209% +$150K 0.07% 192
2015
Q2 		$107K Buy
10,709
+309
+3% +$3.31K 0.05% 230
2015
Q1 		$132K Buy
+10,400
New +$134K 0.07% 183

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PIMJS
PKO Investment Management Joint-Stock Warsaw, Poland $1.38B AUM 59.54% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Advantage Investment Management's KERX Position: Q3 2018 in Review

Advantage Investment Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2018, closing a stake of 9,053 shares — an estimated $34K sold.

Advantage Investment Management first reported a position in KERX in Q1 2015 and held it in 14 quarters. The position peaked at $520K in Q3 2017. 123 funds tracked by Wall St. Rank hold KERX as of Q3 2018.

  • Advantage Investment Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2018 after selling out during the quarter.
  • Advantage Investment Management sold 9,053 Keryx Biopharmaceuticals Inc shares in Q3 2018, an estimated $34K.
  • Advantage Investment Management first reported a position in Keryx Biopharmaceuticals Inc in Q1 2015 and held it in 14 quarters.
  • Advantage Investment Management's Keryx Biopharmaceuticals Inc position peaked at $520K in Q3 2017.
  • 123 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2018.

Based on Advantage Investment Management's 13F filing for Q3 2018, filed 14 Nov 2018.